NCT00991796View on ClinicalTrials.gov

CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

December 31, 2011

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

CS-1008

CS-1008 powder for concentrate for solution for infusion. six cycles of combination therapy with 3 weeks equal to one cycle. 10 mg/kg

DRUG

Placebo

Placebo

DRUG

Paclitaxel

Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2

DRUG

Carboplatin

Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2

Trial Locations (2)

Unknown

Zentrum fur Pneumologie und Thoraxchirurgie, Grobhansdorf

Asklepios Fachkliniken Munchen Gauting, Gauting

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT00991796 - CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter